Literature DB >> 19470852

In vivo SPECT quantification of transplanted cell survival after engraftment using (111)In-tropolone in infarcted canine myocardium.

Kimberley J Blackwood1, Benoit Lewden, R Glenn Wells, Jane Sykes, Robert Z Stodilka, Gerald Wisenberg, Frank S Prato.   

Abstract

UNLABELLED: Current investigations of cell transplant therapies in damaged myocardium are limited by the inability to quantify cell transplant survival in vivo. We describe how the labeling of cells with (111)In can be used to monitor transplanted cell viability in a canine infarction model.
METHODS: We experimentally determined the contribution of the (111)In signal associated with transplanted cell (TC) death and radiolabel leakage to the measured SPECT signal when (111)In-labeled cells were transplanted into the myocardium. Three groups of experiments were performed in dogs. Radiolabel leakage was derived by labeling canine myocardium in situ with free (111)In-tropolone (n = 4). To understand the contribution of extracellular (111)In (e.g., after cell death), we developed a debris impulse response function (DIRF) by injecting lysed (111)In-labeled cells within reperfused (n = 3) and nonreperfused (n = 5) myocardial infarcts and within normal (n = 3) canine myocardium. To assess the application of the modeling derived from these experiments, (111)In-labeled cells were transplanted into infarcted myocardium (n = 4; 3.1 x 10(7) +/- 5.4 x 10(6) cells). Serial SPECT images were acquired after direct epicardial injection to determine the time-dependent radiolabel clearance. Clearance kinetics were used to correct for (111)In associated with viable TCs.
RESULTS: (111)In clearance followed a biphasic response and was modeled as a biexponential with a short (T(1/2)(s)) and long (T(1/2)(l)) biologic half-life. The T(1/2)(s) was not significantly different between experimental groups, suggesting that initial losses were due to transplantation methodology, whereas the T(1/2)(l) reflected the clearance of retained (111)In. DIRF had an average T(1/2)(l) of 19.4 +/- 4.1 h, and the T(1/2)(l) calculated from free (111)In-tropolone injected in situ was 882.7 +/- 242.8 h. The measured T(1/2)(l) for TCs was 74.3 h and was 71.2 h when corrections were applied.
CONCLUSION: A new quantitative method to assess TC survival in myocardium using SPECT and (111)In has been introduced. At the limits, method accuracy is improved if appropriate corrections are applied. In vivo (111)In imaging most accurately describes cell viability half-life if T(1/2)(l) is between 20 h and 37 d.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470852     DOI: 10.2967/jnumed.108.058966

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  Tracking stem cells for cardiovascular applications in vivo: focus on imaging techniques.

Authors:  Yingli Fu; Nicole Azene; Yi Xu; Dara L Kraitchman
Journal:  Imaging Med       Date:  2011-08-01

Review 2.  Noninvasive stem cell tracking.

Authors:  Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2011-10       Impact factor: 5.952

Review 3.  Imaging approaches for the study of cell-based cardiac therapies.

Authors:  Joe F Lau; Stasia A Anderson; Eric Adler; Joseph A Frank
Journal:  Nat Rev Cardiol       Date:  2009-12-22       Impact factor: 32.419

Review 4.  Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke.

Authors:  Yao-Hui Tang; Yuan-Yuan Ma; Zhi-Jun Zhang; Yong-Ting Wang; Guo-Yuan Yang
Journal:  CNS Neurosci Ther       Date:  2015-02-10       Impact factor: 5.243

Review 5.  Technology advancement for integrative stem cell analyses.

Authors:  Yoon Jeong; Jonghoon Choi; Kwan Hyi Lee
Journal:  Tissue Eng Part B Rev       Date:  2014-07-03       Impact factor: 6.389

Review 6.  Cell based therapies for ischemic stroke: from basic science to bedside.

Authors:  Xinfeng Liu; Ruidong Ye; Tao Yan; Shan Ping Yu; Ling Wei; Gelin Xu; Xinying Fan; Yongjun Jiang; R Anne Stetler; George Liu; Jieli Chen
Journal:  Prog Neurobiol       Date:  2013-12-12       Impact factor: 11.685

7.  Positron emission tomography based in-vivo imaging of early phase stem cell retention after intramyocardial delivery in the mouse model.

Authors:  Cajetan Lang; Sebastian Lehner; Andrei Todica; Guido Boening; Wolfgang-Michael Franz; Peter Bartenstein; Marcus Hacker; Robert David
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-17       Impact factor: 9.236

8.  Dynamic In Vivo SPECT Imaging of Neural Stem Cells Functionalized with Radiolabeled Nanoparticles for Tracking of Glioblastoma.

Authors:  Shih-Hsun Cheng; Dou Yu; Hsiu-Ming Tsai; Ramin A Morshed; Deepak Kanojia; Leu-Wei Lo; Lara Leoni; Yureve Govind; Lingjiao Zhang; Karen S Aboody; Maciej S Lesniak; Chin-Tu Chen; Irina V Balyasnikova
Journal:  J Nucl Med       Date:  2015-11-12       Impact factor: 10.057

Review 9.  Biodistribution studies for cell therapy products: Current status and issues.

Authors:  Yoshiteru Kamiyama; Yoichi Naritomi; Yuu Moriya; Syunsuke Yamamoto; Tsukasa Kitahashi; Toshihiko Maekawa; Masahiro Yahata; Takeshi Hanada; Asako Uchiyama; Akari Noumaru; Yoshiyuki Koga; Tomoaki Higuchi; Masahiko Ito; Hiroyuki Komatsu; Sosuke Miyoshi; Sadaaki Kimura; Nobuhiro Umeda; Eriko Fujita; Naoko Tanaka; Taku Sugita; Satoru Takayama; Akihiko Kurogi; Satoshi Yasuda; Yoji Sato
Journal:  Regen Ther       Date:  2021-07-12       Impact factor: 3.419

Review 10.  Hybrid PET/MR imaging in myocardial inflammation post-myocardial infarction.

Authors:  B Wilk; G Wisenberg; R Dharmakumar; J D Thiessen; D E Goldhawk; F S Prato
Journal:  J Nucl Cardiol       Date:  2019-12-03       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.